Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Sandoz Optimistic on Golden Decade for US Biosimilars and Affordable Medicines
Sandoz eyes $322B opportunity in the biosimilar void, predicting a golden decade of affordable medicines despite US market challenges.
Worldwide Clinical Trials to Acquire Oncology CRO Catalyst Clinical Research
Worldwide Clinical Trials enters agreement to acquire oncology CRO Catalyst Clinical Research. Deal to conclude Q1 2026, enhancing global reach.
BioNxt ODF Cladribine Shows 40% Higher Delivery for Multiple Sclerosis
BioNxt reports sublingual ODF cladribine achieved 40% higher systemic delivery than oral tablets for Multiple Sclerosis treatment in preclinical study.
FDA Grants Breakthrough Therapy to Novartis' Ianalumab for Sjögren's Disease
Novartis receives FDA Breakthrough Therapy tag for ianalumab treating Sjögren's disease after positive Phase III NEPTUNUS results. Filings in 2026.
Indian Pharma Exports Surge: Brazil & Nigeria Emerge as Key Markets in FY26
Indian pharmaceutical exports rose 6.5% to $20.48B. Brazil and Nigeria join the US as top destinations for Indian generics in April-November FY26.
Nucleome Nominates NTP464: First Antibody Agonist for Inflammation Resolution
Nucleome Therapeutics nominates NTP464, a first-in-class antibody agonist for autoimmune diseases, discovered via its 3D genetics MCC platform.
Nxera Reports Positive Phase III Results for Daridorexant in South Korea
Nxera Pharma announces positive Phase III results for daridorexant (Quviviq) in South Korea. Plans for marketing authorization application in Q1 2026.
China Medicine Exports Hit $100B, Licensing Deals Soar to $135B in 2025
Chinese medicine exports reached $100.9B in 2025. Out-licensing deals hit a record $135.7B. New trade platforms boost ties with ASEAN and global markets.
Vibrant Therapeutics Raises $61m to Advance VIB305 and Intelligent Pipeline
Vibrant Therapeutics secures $61m from Pfizer Ventures to advance VIB305, a masked T-cell engager for EGFR solid tumours, and enters US trials.
Axsome begins Phase III AXS-14 FORWARD trial for fibromyalgia management
Axsome initiates FORWARD Phase III trial evaluating AXS-14 (esreboxetine) for fibromyalgia management, affecting 17 million in the US.
STDP Improves Coronary Blood Flow in Angina Patients: Phase IV Trial Results
New phase IV data show Shexiang Tongxin Dropping Pill (STDP) improves coronary blood flow (CSFP) in angina patients by reducing CTFC with high safety.
J&J Caplyta Doubles Remission Rates in MDD: New Phase III Data
New analysis from Phase III trials shows J&J’s Caplyta (lumateperone) nearly doubles remission likelihood in MDD patients. Explore clinical data and market outlook.
33
34
35
36
37
38
39
40
41
